Federated Hermes’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Federated Hermes’s Portfolio CYT Stock Details CYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-208	Closed	-$541	–	2233
2023 Q2	$541	Hold	208	–	–	﹤0.01%	2054
2023 Q1	$379	Buy	+208	New	+$338	﹤0.01%	2089

Other funds holding CYT

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

OMC

OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

VAS

VR Advisory Services Camana Bay, Grand Cayman, Cayman Islands $845M AUM 22.79% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return

Federated Hermes's CYT Position: Q3 2023 in Review

Federated Hermes sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q3 2023, closing a stake of 208 shares — an estimated $541 sold.

Federated Hermes first reported a position in CYT in Q1 2023 and held it in 2 quarters. The position peaked at $541 in Q2 2023. 41 funds tracked by Wall St. Rank hold CYT as of Q3 2023.

Federated Hermes reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Federated Hermes sold 208 Cyteir Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $541.
Federated Hermes first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q1 2023 and held it in 2 quarters.
Federated Hermes's Cyteir Therapeutics, Inc. Common Stock position peaked at $541 in Q2 2023.
41 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Federated Hermes's 13F filing for Q3 2023, filed 13 Nov 2023.